The development of novel inhibitors of tumor necrosis factor-α (TNF-α) production based on substituted [5,5]-bicyclic pyrazolones
- 1 August 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (16) , 4267-4272
- https://doi.org/10.1016/j.bmcl.2004.06.001
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Development of Orally Bioavailable Bicyclic Pyrazolones as Inhibitors of Tumor Necrosis Factor-α ProductionJournal of Medicinal Chemistry, 2004
- Anti-TNF-α therapies: the next generationNature Reviews Drug Discovery, 2003
- Therapeutic strategies for rheumatoid arthritisNature Reviews Drug Discovery, 2003
- MAP KinasesChemical Reviews, 2001
- Mono‐iodoacetate‐induced experimental osteoarthritis. A dose‐response study of loss of mobility, morphology, and biochemistryArthritis & Rheumatism, 1997
- Crystallization and preliminary crystallographic analysis of recombinant human p38 MAP kinaseProtein Science, 1997
- Cytokines in autoimmunityCurrent Opinion in Immunology, 1996
- A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian CellsScience, 1994
- Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processingNature, 1994
- 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans As cell-viability indicatorsBioorganic & Medicinal Chemistry Letters, 1991